Simon Quick Advisors LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Simon Quick Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 682 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Several other institutional investors have also recently made changes to their positions in ALNY. Brighton Jones LLC purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $243,000. Principal Financial Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 234.4% during the first quarter. Principal Financial Group Inc. now owns 34,701 shares of the biopharmaceutical company’s stock valued at $9,370,000 after buying an additional 24,323 shares during the period. OneDigital Investment Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 15.8% in the 1st quarter. OneDigital Investment Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock valued at $327,000 after acquiring an additional 165 shares during the period. Penserra Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 10,066.7% in the 1st quarter. Penserra Capital Management LLC now owns 1,220 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 1,208 shares during the period. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 9.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 72,047 shares of the biopharmaceutical company’s stock valued at $19,454,000 after acquiring an additional 6,033 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a research note on Friday, August 1st. Citigroup lifted their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research note on Monday, October 6th. Finally, Wolfe Research upgraded Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday, August 4th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $478.67.

Alnylam Pharmaceuticals Stock Down 2.4%

Shares of ALNY opened at $423.47 on Wednesday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The stock has a 50 day moving average price of $459.45 and a 200 day moving average price of $373.65. The stock has a market capitalization of $55.51 billion, a price-to-earnings ratio of -171.45 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $1.51. The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $943.37 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s quarterly revenue was up 149.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.50) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the transaction, the executive vice president directly owned 25,231 shares in the company, valued at approximately $11,405,673.55. This represents a 8.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 8,924 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the transaction, the chief executive officer owned 65,409 shares of the company’s stock, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 98,144 shares of company stock worth $44,160,261 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.